T. Rowe Price Reports 2.3% Stake in Blueprint Medicines (BPMC) — 1.47M Shares

T. Rowe Price Associates, Inc. filed Amendment No. 9 to a Schedule 13G disclosing its holdings in Blueprint Medicines Corp common stock.

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed Amendment No. 9 to a Schedule 13G disclosing its holdings in Blueprint Medicines Corp common stock. The filing reports an aggregate beneficial ownership of 1,465,036 shares, representing 2.3% of the class, with sole voting power of 1,429,561 shares and sole dispositive power of 1,459,988 shares. The statement affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The form is signed by Ellen York, Vice President, dated 08/14/2025.

Insights

Financial Analyst

TL;DR: T. Rowe Price reports a modest 2.3% passive stake in Blueprint Medicines; this is a routine institutional disclosure with limited market impact.

The filing quantifies holdings precisely: 1,465,036 shares (2.3%) with clear delineation of voting and dispositive power. Because the filer uses Schedule 13G and certifies the position is held in the ordinary course and not to influence control, this indicates a passive investment rather than an activist or control intent. For investors, the data confirms institutional ownership but does not signal strategic change at the issuer level.

Corporate Governance Expert

TL;DR: Amendment to Schedule 13G confirms passive beneficial ownership and compliance with disclosure rules; no governance intent asserted.

The registrant explicitly states the securities were not acquired to influence control and files under Schedule 13G procedures, which is consistent with passive institutional ownership. The filing lists specific powers: sole voting power 1,429,561 and sole dispositive power 1,459,988, and includes the required certification language. This is a standard compliance disclosure rather than a governance action.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price report in Blueprint Medicines (BPMC)?

The filing reports 1,465,036 shares, equal to 2.3% of the class.

How many shares does T. Rowe Price have voting and dispositive power over?

The filer reports sole voting power for 1,429,561 shares and sole dispositive power for 1,459,988 shares.

Does the Schedule 13G/A state T. Rowe Price intends to influence control of Blueprint Medicines?

No. The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who signed the Schedule 13G/A for T. Rowe Price and when?

The form is signed by Ellen York, Vice President, dated 08/14/2025.

Under what rule was this Schedule 13G filed?

The document identifies filing under Rule 13d-1 related procedures for institutional investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 01:07 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

BLUEPRINT MEDICINES CORP

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

09627Y109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09627Y109

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,429,561.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,459,988.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,465,036.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BLUEPRINT MEDICINES CORP
(b)	Address of issuer's principal executive offices: 45 SIDNEY STREET, CAMBRIDGE, MA, 02139
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 09627Y109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1465036
(b)	Percent of class: 2.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1429561
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1459988
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2025